THE SAFETY AND TOLERABILITY OF MULTIPLE DOSE ADMINISTRATION OF CSL112, AN INTRAVENOUS FORMULATION OF PLASMA-DERIVED APOA-I, AMONG SUBJECTS WITH MODERATE RENAL IMPAIRMENT AFTER ACUTE MYOCARDIAL INFARCTION

Authors :: Danielle Duffy
Christoph Bode
Mathieu Kerneis
Megan Yee
John Feaster
Basil Lewis
John Kastelein
C. Michael Gibson
Yazan Daaboul
Roxana Mehran
Daniel Duerschmied
Pierluigi Tricoci
Dominick J. Angiolillo
John Alexander
Ali Poyan Mehr
Ton Oude Ophius
Bela Merkely
Serge Korjian
Majdi Halabi
Ravindra Mehta
Source :: Journal of the American College of Cardiology. 71:A165
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.
Abstract: CSL112 is plasma-derived apolipoprotein A-I (apoA-I), currently in development for early reduction of cardiovascular risk after acute myocardial infarction (AMI). The AEGIS-I trial demonstrated renal and hepatic safety and elevations in cholesterol efflux with 4 weekly intravenous infusions of 2g or

Full Text Access

Tools